Navigation Links
China Biologic Products Provides Preliminary Guidance for 2009 of Revenues of $90 to $100 Million and Net Income of $18 to 22 Million
Date:10/16/2008

to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

For more information, please contact:

Company Contact:

Mr. Chao Ming Zhao

CEO

China Biologic Products, Inc.

Tel: +86-538-6217079

Email: IR@chinabiologic.com

http://www.chinabiologic.com

Investor Relations Contact:

Mr. Crocker Coulson

President

CCG Investor Relations

Tel: +1-646-213-1915 (NY office)

Email: crocker.coulson@ccgir.com

http://www.ccgir.com


'/>"/>
SOURCE China Biologic Products, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
4. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
5. China Technology Announces New Chief Financial Officer
6. China Medical Technologies Reports First Quarter Financial Results
7. China Medical Technologies to Participate in Credit Suisses 2007 Asian Technology Conference
8. China Technology Announces Entry to the Solar Energy Sector
9. China Sky One Medical Receives $1.5 Million Government Grant to Further Develop Six New Cancer Products
10. Kiwa Bio-Tech Named Recommended Brand by the China Green Food Association
11. China Kangtai Cactus Biotech, Inc. Announces Plans for New Product Launch
Post Your Comments:
*Name:
*Comment:
*Email:
Other Biology Technology:Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board 2Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board 3OncologySTAT Advisors Name Year's Top Developments in Cancer Treatment and Research 2OncologySTAT Advisors Name Year's Top Developments in Cancer Treatment and Research 3OncologySTAT Advisors Name Year's Top Developments in Cancer Treatment and Research 4Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009 2Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009 3Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009 4Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009 5Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009 6Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009 7Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009 8Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009 9Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009 10